Drugs / cetilistat
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00148382 | Apr → Jul 2005 | obesity disorder | Alizyme | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00156897 | Dec 2004 → Oct 2005 | obesity disorder, type 2 diabetes mellitus | Alizyme | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cetilistat | “The objective of this multicenter, randomized, double-blind study was to determine the efficacy and safety of cetilistat and orlistat relative to placebo in obese patients with...” PMID 19461584 ↗ May 2009 |
| Known as | ATL-962 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00148382 ↗ |
| Action | Inhibit | “ATL-962 is a lipase inhibitor” NCT00148382 ↗ |
| Modality | Small molecule | — CHEMBL2103825 ↗ |
| Target | LIPF | “Gastric lipase inhibitor” CHEMBL2103825 ↗ |
| Target | PNLIP | “Pancreatic lipase inhibitor” CHEMBL2103825 ↗ |